SCHEMBL3012665

SCHEMBL3012665

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)N1CCN(c2nc(-c3cccc(Br)c3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.52
MAPT P10636 5/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ALDH1A1 P00352 3/20 0.49
LMNA P02545 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TSHR P16473 1/20 0.48
ATM Q13315 1/20 0.48
RAB9A P51151 3/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPK1 P28482 2/20 0.45
TP53 P04637 1/20 0.42
NPC1 O15118 1/20 0.40
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652846 0.93 MAPT (0.60) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3006723 0.90 LMNA (0.57) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3010739 0.89 AR (0.52) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3014345 0.89 AR (0.49) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3011631 0.88 AR (0.54) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3016174 0.88 MEN1 (0.50) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3003370 0.87 MAPT (0.66) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3011261 0.86 AR (0.57) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3012132 0.86 ALDH1A1 (0.53) ARMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL3013011 0.86 SMN1; SMN2 (0.54) ARMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.